For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting)
|09/01/2013||31/01/2013||Full Pharmacoeconomic Evaluation Recommended|
|24/05/2013||27/08/2013||Reimbursement not recommended|
The NCPE do not consider Crizotinib (Xalkori®) a cost-effective treatment for adult patients with previously treated ALK positive advanced non small cell lung cancer (NSCLC).
The HSE has approved reimbursement following confidential price negotiations.